Research Article
Prognostic Significance of Percutaneous Coronary Intervention for First Acute Myocardial Infarction with Heart Failure: Five-Year Follow-Up Results
Table 3
Medication during hospitalization.
| | Variables | HF group (n = 97) | Non-HF group (n = 512) | P |
| | Aspirin n (%) | 57 (100) | 301 (100) | | | Clopidogrel n (%) | 88 (90.72) | 440 (85.93) | 0.277 | | Ticagrelor n (%) | 9 (9.27) | 72 (14.06) | 0.218 | | LMWH n (%) | 95 (97.93) | 498 (97.26) | 0.704 | | GP IIb/IIIa inhibitor n (%) | 61 (62.88) | 258 (50.39) | 0.040 | | β-Receptor blocker n (%) | 92 (94.84) | 451 (88.08) | 0.050 | | ACEI/ARB n (%) | 84 (86.59) | 408 (79.68) | 0.272 | | Loop diuretics n (%) | 10 (10.30) | 30 (5.85) | 0.246 | | Statins n (%) | 97 (100) | 511 (99.80) | 0.663 | | Spironolactone n (%) | 11 (11.34) | 14 (2.73) | ≤0.001 | | Antidiabetic drugs n (%) | 12 (12.37) | 85 (16.60) | 0.296 | | Insulin n (%) | 10 (10.30) | 44 (8.59) | 0.5.86 |
|
|
LMWH: low-molecular-heparin; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blocker.
|
